« Biotherapies / Bioproduction / Pharma» is one of the four key areas of excellence at Atlanpole Biotherapies. It spans multiple technological domains, including immunotherapy, radiopharmaceuticals, cell therapy, gene therapy, phage therapy, marine bioresources, and synthetic molecules…
This focus echoes the strategies implemented by the French Government to ensure national sovereignty in the production of Advanced Therapy Medicinal Products (ATMPs) (including gene therapy medicines, cell therapy medicines, medicines derived from cell or tissue engineering, and combined advanced therapy medicinal products) and to accelerate the development of biotherapies (recombinant proteins, antibodies, vaccines).
In recent years, France has adopted a strong and proactive policy to support biopharmaceutical innovation and the localization/relocation of production facilities within its territory, notably through the Strategic Committee for the « Health Industries and Technologies Sector» (CSF ITS) and the « Biotherapies and Bioproduction of Innovative Therapies » acceleration strategy.
These measures aim to multiply the productivity of biopharmaceuticals in France in order to reduce production costs and timelines, thereby facilitating patient access.
ACTIONS LED BY THE CLUSTER
Pioneer in biotherapeutic innovation, Atlanpole Biotherapies has created a particularly supportive ecosystem to implement this national policy and structure the sector across its territory (Pays de la Loire, Brittany, and Centre-Val de Loire).
Support and Guidance for Innovation Projects
As an expert in collaborative projects, the cluster offers its members a comprehensive support system, including project engineering, partner search, and funding assistance.
In 2023, 64% of the projects within the
« Biotherapies / Bioproduction / Pharma » focus area were awarded the cluster label, and 12 of them received funding.
By leveraging national funding mechanisms such as the France Relance recovery plan and capitalizing on calls for proposals under France 2030 the cluster contributes to the financing of R&D projects mainly industrial as well as investment projects aimed at strengthening production capabilities.
Since its launch in 2022, the France 2030 plan has recognized 41 member organizations of the cluster for their innovation projects.
Previously, in 2021, 7 projects were supported under the France Relance initiative.
These major structuring projects form a solid foundation for accelerating the development of biopharmaceuticals and synthetic drugs in the Greater West of France.
Examples of Supported Projects
MESPRCC led by |
MESHCAP |
PACT3 by |
| Modernize, expand, and diversify the operations of Biowest’s industrial site dedicated to the production of cell culture products, essential consumables for the development of advanced therapy medicines, particularly biopharmaceuticals. | Develop a relevant mouse model of small cell lung cancer for the preclinical evaluation of innovative immunotherapies against this cancer, which is resistant to existing treatments. | Develop an innovative therapeutic approach combining an antibody with an enzyme to selectively target and neutralize pathogenic antibodies produced by the body against itself, which are responsible for thrombosis (the formation of clots that can block blood vessels) and thrombocytopenia (a reduction in blood platelets that increases the risk of bleeding). |
| Awarded funding : 1,034 M€ | Awarded funding : 75 K€ | Awarded funding : 345 K€ |
Would you also like support for your R&D or innovation project in the field of ” Biotherapies / Bioproduction / Pharma” ?
Learn more about our support➡
Strategic Partnerships
To enable collaborative research, the cluster has established strategic partnerships since its creation with:
- Innovation support stakeholders: French health competitiveness clusters (Medicen, BioValley France, Eurobiomed, Lyonbiopôle), other regional clusters (EMC2, Images & Réseaux, Pôle Mer Bretagne Atlantique, Polymeris), clusters (Polepharma, Biotech Santé Bretagne) and innovation support organizations (technopoles, CEA Tech)
- Academic stakeholders: research laboratories and institutes, technological research institutes (B<>com, Jules Verne), leading engineering schools and training institutions (Oniris, Bio3 Institute, IMT Atlantique) and technology resource centers (WeNetwork / Cap’Tronic)…
- Networks and associations such as France BioLead of which the cluster is a member, to contribute to the structuring of the national bioproduction sector.
These partnerships foster public-private cooperation, enabling the cluster’s member SMEs to collaborate with a wide range of committed actors in the development of new biotherapies, pharmaceutical specialties, and/or technologies designed to improve production processes.
Event Organization
Workshops, training sessions, webinars, major international biotechnology trade shows (BioFIT, BIO International Convention, BIO-EUROPE Spring)… The cluster organizes numerous events to bring its members together around its strategic focus area « Biotherapies / Bioproduction / Pharma» fostering networking opportunities and discussions on shared topics of interest.
Each year, Atlanpole Biotherapies is also a partner of the Congrès France Bioproduction which brings together nearly 500 stakeholders from the pharma and biopharma sectors.
Atlanpole Biotherapies organizes and co-organizes over 30 events each year!
Check out our event calendar ➡
THEY ARE PART OF THE NETWORK
Atlanpole Biotherapies brings together an ecosystem of over 200 members.
The biotechnology and pharmaceutical industries are strongly represented, with numerous companies and organizations such as: Abcely, AbolerIS Pharma, Affilogic, AGS Therapeutics AI4R, AlgoSource, Arronax, AtlanChim Pharma, Atlanthera, Atlantic Bone Screen, Atonco, Bio Logbook, BioMAdvanced Diagnostics, Biomatlante, Biotrial Pharmacology, Chelatec, Clean Biologics, Clean Cells, ERBC, GenSensor, GlioCure, GLYcoDiag, Hemarina, Igyxos Biotherapeutics, InFlectis BioScience, Kalsiom, Lemer Pax, McSAF, M SE, Naobios, Naogen Pharma, NG Biotech, OGD2 Pharma, Olgram, OSE Immunotherapeutics, Parean Biotechnologies, Promega, SeaBeLife Biotech, SLB Pharma, Thermo Fisher Scientific, Valneva, Wepredict, Xenothera…
And let’s not forget the academic community, with over 40 laboratories, institutes, top-tier schools, and healthcare institutions spread across the cluster’s territory. Discover all our members➡
HAVE A QUESTION?
Contact our « Biotherapies / Bioproduction / Pharma»
Johann DION
Scientific & Technical Manager
dion@atlanpole.fr
+33 (0)6 74 29 84 06 / +33 (0)2 40 25 18 48